Skip to main content
SpringerLink
Log in

Less is more: a cost benefit analysis of a changed posology for nivolumab

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. European Medicines Agency (2019) Opdivo Annex I Summary of Product Characteristics [Internet]. Amsterdam NED: European Medicines Agency; [updated 2019 August 1; cited 2019 November 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf

  2. European Medicines Agency (2019) Opdivo Procedural steps taken and scientific information after authorisation [Internet]. Amsterdam NED: European Medicines Agency; [updated 2019 June 11; cited 2019 November 21]. Available from: https://www.ema.europa.eu/en/documents/procedural-steps-after/opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf

  3. Dutch Hospital Database (2019) Drug monitor. Utrecht NED: Dutch Hospital Database; [updated 2019 August 1; cited 2019 November 21]. Available from: https://www.dhd.nl/producten-diensten/GM/Paginas/geneesmiddelenmonitor.aspx

  4. Bristol-Myers Squibb (2018) Bristol-Myers Squibb reports fourth quarter and full year financial results [internet]. New York USA: Bristol-Myers Squibb; [updated 2019 January 24; cited 2019 November 21]. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-reports-fourth-quarter-and-full-year-fi-0

  5. Bayle A, Besse B, Annereau M et al (2019) Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact? Eur J Cancer 113:28–31

    Article  Google Scholar 

  6. Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH (2017) Fixed dosing of monoclonal antibodies in oncology. Oncologist. 22:1212–1221

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, PO Box 5500, NL 6130 MB, Sittard-Geleen / Heerlen, The Netherlands

    N. W. Boone

  2. Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen / Heerlen, The Netherlands

    A. A. van Bodegraven

Authors
  1. N. W. Boone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. van Bodegraven
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors have contributed equally to the creation of the article.

Corresponding author

Correspondence to N. W. Boone.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boone, N.W., van Bodegraven, A.A. Less is more: a cost benefit analysis of a changed posology for nivolumab. Eur J Clin Pharmacol 76, 739–740 (2020). https://doi.org/10.1007/s00228-020-02839-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-02839-7

Search

Navigation